Skip to content

Laryngeal Mask Airways Are Supraglottic Devices Used to Maintain Airway Patency During Anesthesia and in Difficult Airways. IV Dexmedetomidine Improves LMA Insertion Success and Decreases Coughing, While IV Lidocaine Decreases Postoperative Cough.

Intravenous Dexmedetomidine Vs. Lidocaine for Laryngeal Mask Insertion Conditions In Pediatric Patients Undergoing Elective Surgeries, A Randomized Controlled Trial.

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07562308
Acronym
DEX LMA
Enrollment
60
Registered
2026-05-01
Start date
2026-05-01
Completion date
2026-09-30
Last updated
2026-05-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pediatric, Elective, Surgery in Early Childhood

Keywords

Dexmedetomidine, Lidocaine, LMA, Pediatrics, Elective

Brief summary

Laryngeal Mask Airways Are Supraglottic Devices Used to Maintain Airway Patency During Anesthesia and in Difficult Airways. LMA may help in reducing postoperative pulmonary complications. IV Dexmedetomidine Improves LMA Insertion Success and Decreases trials number, While IV Lidocaine Decreases Postoperative Cough. This is a randomized interventional trial comparing both drugs. IV DEX will be compared vs IV lidocaine regarding the feasibility of insertion, number of trials, incidence of cough, postoperative pulmonary complications and hemodynamic profile.

Interventions

IV 0.2 mic/ kg of dexmedetomidine will be diluted over 10 ml saline and given to the patient over 10 minutes before induction and assess the feasibility of classic LMA insertion

DRUGLidocaine (drug)

IV 1.5 mg/kg of lidocaine will be diluted over 10 ml saline and given to the patient 1 minute before induction and assess the feasibility of classic LMA insertion

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
2 Years to 12 Years
Healthy volunteers
No

Inclusion criteria

* Parental/guardian consent. * Age 2-12 years * ASA physical status I-II. * Elective surgery requiring LMA (duration \<2 hours).

Exclusion criteria

* Known airway anomalies (e.g., tonsillar hypertrophy, cleft palate). * Cardiovascular disease (bradycardia, arrhythmias). * Allergy to study drugs. * BMI \>95th percentile.

Design outcomes

Primary

MeasureTime frameDescription
First-attempt insertion success rateAfter induction of anesthesiaThe success of the first trial of classic LMA insertion will be assessed. Binary: yes or no.

Secondary

MeasureTime frameDescription
Ease of insertion (4-point scale)After Induction of anesthesiaGrade 1: No resistance. Grade 2: Mild resistance. Grade 3: Moderate resistance. Grade 4: Failed insertion and need for another airway management tool.
Heart rateEvery 15 minutes till recoveryMonitored continuously and recorded every 15 minutes. Atropine IV will be given if bradycardia occurs.
MAPEvery 15 minutesMean arterial blood pressure
Recovery TimeAfter cessation of anesthesia administrationTime from discontinuation of anesthesia till the child is fully awake.
Postoperative AgitationIn PACUPAED scale 1. The child makes eye contact with the caregiver 2. The child's actions are purposeful 3. The child is aware of his/her surroundings 4. The child is restless 5. The child is inconsolable
Postoperative Complications0,1,2,6 hours postoperative.Laryngeal Spasm, Coughing
PONV24 hours postoperativePONV grade Patient response 0 Without PONV I Nausea without vomiting II Nausea with vomiting (\< 3 times/d) III Vomiting ≥ 3 times/d
Postoperative sore throat (0-3 scale).24 hours postoperative0 (none) 1. (mild/complaint only upon asking) 2. (moderate/complaint on own) 3. (severe/hoarseness or throat pain).

Countries

Egypt

Contacts

CONTACTAbdelrahman Hamdy, Lecturer
abdelrahmanhm89@gmail.com+201060989574
CONTACTMohammed Adel, Lecturer
01050727722
PRINCIPAL_INVESTIGATORAbdelrahman Hamdy

Asyut University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 13, 2026